MKI67 and breast cancer: A total of 29 studies investigated 17 distinct factors concerning CMDs (Table 2), with 28 studies assessing non-prognostic outcomes, including high grade (n = 16), (micro)invasion (n = 8), (comedo)necrosis (n = 7), HER2 overexpression (n = 6), ER positivity (n = 6), age (n = 3), Ki67 or proliferation (n = 2), histological size (n = 2), neoductgenesis (n = 2), calcification distribution (n = 2), margin status (n = 1), comedocarcinoma (n = 1), multicentricity (n = 1), tenascin-C (n = 1), and Oncotype DX score (n = 1).